['myocardial infarction']
['fulacimstat (bay1142524)', 'placebo']

        Inclusion Criteria:

          -  Patients with first ST elevation myocardial infarction (STEMI) treated with primary
             percutaneous intervention (PCI) or thrombolysis within 24 hours after symptom onset

          -  Diagnosis of STEMI requires the presence of the following three criteria:

               -  Typical clinical symptoms such as chest pain, shortness of breath for more than
                  20 minutes related to the myocardial infarction

               -  New ST elevation indicating myocardial infarction

               -  Significant elevation in troponin T or I with at least one value above the 99th
                  percentile upper reference limit (URL) and/or elevation creatine kinase (CK) and
                  creatine kinase MB (6-10% of total CK)

          -  At the screening period, on day 5 to 9 after MI, patients have to have a LVEF ≤ 45%
             and an infarct size >10% LV mass (as measured by LGE-MRI, central-blinded evaluation)

        Exclusion Criteria:

          -  Contraindication to perform contrast-enhanced cardiac MRI

          -  LVEF < 20%

          -  History of heart failure or LVEF < 50% before occurrence of the first STEMI

          -  Infarct size > 45% (g/g; LV mass) between 5 and 9 days after myocardial infarction

          -  NYHA (New York Heart Association) class IV at randomization

          -  Any planned cardiac intervention after baseline MRI or any other planned operations

          -  Non-ischemic causes for cardiomyopathy

          -  Diagnosis of atrial fibrillation

          -  Systolic blood pressure < 100 mm Hg or > 180 mm Hg; diastolic blood pressure < 50 mm
             Hg or >110 mm Hg, heart rate < 50 or >100 beat/minute; mean of triplicate values at
             randomization

          -  Clinically relevant hepatic dysfunction
      